In 2023, the global genomics artificial intelligence market size reached $11.5 billion and is expected to reach $19.72 billion by 2030, with a compound annual growth rate of 50.1%. The surge in genomic data is driving the application of AI in genomics, accelerating drug discovery and diagnostics, while reducing costs. Increased awareness among medical professionals and the public about the potential benefits of AI in genomics is propelling market demand. During the forecast period, on-premise delivery models are expected to dominate the global genomics artificial intelligence market.

Cancer detection startup C2i Genomics has partnered with Tel Aviv's Sourasky Medical Center, Israel's top hospital, to utilize cloud-based artificial intelligence solutions for early cancer detection. C2i Genomics focuses on whole-genome minimal residual disease (MRD) detection to enhance cancer detection and monitoring capabilities. The collaboration will advance internal research and clinical trials at the hospital and facilitate drug development for pharmaceutical companies.

{1:C2i Genomics, a cancer detection startup, collaborates with Israel's top hospital, Tel Aviv Sourasky Medical Center, to utilize cloud-based AI solutions for early cancer detection. 2:C2i Genomics focuses on whole genome minimal residual disease (MRD) detection to enhance the ability to detect and monitor cancer. 3:The collaboration will drive internal research and clinical trials at the hospital and promote drug development by pharmaceutical companies.}